Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | CCR2 | P41597 | 13/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9930912 | 0.91 | SMN1; SMN2 (0.71) | SMN1; SMN2CCR2ALDH1A1NPSR1TP53 | |
| SCHEMBL9973037 | 0.88 | CCR2 (0.55) | SMN1; SMN2CCR2 | |
| SCHEMBL9931292 | 0.83 | CCR2 (0.69) | SMN1; SMN2CCR2ALDH1A1TP53 | |
| SCHEMBL9930906 | 0.82 | SMN1; SMN2 (0.67) | SMN1; SMN2CCR2ALDH1A1TP53 | |
| SCHEMBL9930357 | 0.81 | CCR2 (0.55) | SMN1; SMN2CCR2ALDH1A1 | |
| SCHEMBL9930608 | 0.81 | TDP1 (0.57) | SMN1; SMN2CCR2ALDH1A1NPSR1 | |
| SCHEMBL16747602 | 0.79 | CCR2 (0.61) | SMN1; SMN2CCR2ALDH1A1TP53 | |
| SCHEMBL9973047 | 0.78 | SMN1; SMN2 (0.58) | SMN1; SMN2CCR2ALDH1A1TP53 | |
| SCHEMBL9930682 | 0.78 | CCR2 (0.76) | SMN1; SMN2CCR2ALDH1A1 | |
| SCHEMBL9930851 | 0.78 | CCR2 (0.72) | SMN1; SMN2CCR2ALDH1A1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9603834-B2 | 1,2- bis-sulfonamide derivatives as chemokine receptor modulators | ALLERGAN, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| US-20160228407-A1 | NOVEL 1,2- BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. | 2016-08-11 | — | — | US | disclosed |
| US-20140221351-A1 | NOVEL 1,2- BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-8729066-B2 | 1,2- bis-sulfonamide derivatives as chemokine receptor modulators | ALLERGAN, INC. (US) | 2014-05-20 | — | — | US | disclosed |
| US-20140051682-A1 | NOVEL 1,2- BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-8580779-B2 | 1,2-bis-sulfonamide derivatives as chemokine receptor modulators | ALLERGAN, INC. (US) | 2013-11-12 | — | — | US | disclosed |
| US-20120157444-A1 | NOVEL 1,2- BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160228407-A1 | NOVEL 1,2- BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | CXCR2, CCR2, CX3CR1 | SMN1; SMN2 4557/4885CCR2 2/4885ALDH1A1 2379/4885 |
| US-20140051682-A1 | NOVEL 1,2- BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | CXCR2, CCR2, CX3CR1 | SMN1; SMN2 4557/4885CCR2 2/4885ALDH1A1 2379/4885 |
| US-20140221351-A1 | NOVEL 1,2- BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | CXCR2, CCR2, CX3CR1 | SMN1; SMN2 4557/4885CCR2 2/4885ALDH1A1 2379/4885 |
| US-20120157444-A1 | NOVEL 1,2- BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | CXCR2, CCR2, CX3CR1 | SMN1; SMN2 4557/4885CCR2 2/4885ALDH1A1 2379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.